Clinical Trials Directory

Trials / Unknown

UnknownNCT02533609

Elimination of Antibiotics During Citrate-anticoagulated Continuous-veno-venous-haemodialysis

Status
Unknown
Phase
Study type
Observational
Enrollment
30 (estimated)
Sponsor
Heinrich-Heine University, Duesseldorf · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Acute kidney injury (AKI) requiring renal replacement therapy is common in critically ill patients. The major causes of AKI are severe sepsis and septic shock requiring effective antibiotic treatment. Patients with sepsis on ICUs usually are haemodynamically instable so that renal replacement therapy is applied using continuous techniques. In recent years, the efficacy of renal replacement therapies has improved, namely by using regional citrate anticoagulation which improves filter lifetime and filter patency. At present, the extent of removal of antibiotic drugs using citrate-anticoagulated CVVHD in critically ill patients has not been investigated thoroughly. Thus, the investigators want to investigate 1. whether and to what extent antibiotic drugs (piperacillin/tazobactam and imipenem/cilastatin) are removed during citrate-anticoagulated CVVHD per se 2. whether filter patency during citrate-anticoagulated CVVD remains stable during a treatment period of 72 h

Conditions

Timeline

Start date
2015-09-01
Primary completion
2020-08-01
Completion
2020-12-01
First posted
2015-08-27
Last updated
2020-05-11

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT02533609. Inclusion in this directory is not an endorsement.

Elimination of Antibiotics During Citrate-anticoagulated Continuous-veno-venous-haemodialysis (NCT02533609) · Clinical Trials Directory